NASDAQ:CDMO Avid Bioservices (CDMO) Stock Price, News & Analysis $10.15 -0.05 (-0.49%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Avid Bioservices Stock (NASDAQ:CDMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avid Bioservices alerts:Sign Up Key Stats Today's Range$10.10▼$10.2850-Day Range$8.83▼$12.4552-Week Range$4.07▼$12.48Volume457,395 shsAverage Volume1.10 million shsMarket Capitalization$647.47 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company OverviewAvid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Avid Bioservices Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreCDMO MarketRank™: Avid Bioservices scored higher than 77% of companies evaluated by MarketBeat, and ranked 274th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAvid Bioservices has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAvid Bioservices has only been the subject of 3 research reports in the past 90 days.Read more about Avid Bioservices' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avid Bioservices are expected to grow in the coming year, from ($0.29) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avid Bioservices' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.94% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Avid Bioservices has recently increased by 1.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-0.96 Percentage of Shares Shorted19.94% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Avid Bioservices has recently increased by 1.11%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.64 News SentimentAvid Bioservices has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Avid Bioservices this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $194,208.00 in company stock.Percentage Held by InsidersOnly 3.05% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions97.16% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avid Bioservices' insider trading history. Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Stock News HeadlinesInsider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) Insider Sells 2,031 Shares of StockOctober 12, 2024 | insidertrades.comAvid Bioservices, Inc. (NASDAQ:CDMO) Insider Sells $20,411.55 in StockOctober 14 at 5:38 AM | americanbankingnews.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 17, 2024 | Porter & Company (Ad)Insider Selling: Avid Bioservices, Inc. (NASDAQ:CDMO) CEO Sells $172,588.65 in StockOctober 14 at 4:50 AM | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Shares Gap Down - Here's What HappenedOctober 10, 2024 | americanbankingnews.comAvid Bioservices (NASDAQ:CDMO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comAvid Bioservices to Participate in Craig-Hallum Bioprocessing ConferenceSeptember 12, 2024 | globenewswire.comAvid Bioservices Shares Gain Following Higher Revenue, Positive OutlookSeptember 11, 2024 | marketwatch.comSee More Headlines CDMO Stock Analysis - Frequently Asked Questions How have CDMO shares performed this year? Avid Bioservices' stock was trading at $6.50 at the beginning of the year. Since then, CDMO stock has increased by 56.2% and is now trading at $10.15. View the best growth stocks for 2024 here. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Monday, September, 9th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company earned $40.17 million during the quarter, compared to analysts' expectations of $39.50 million. Avid Bioservices had a negative net margin of 101.26% and a negative trailing twelve-month return on equity of 16.53%. When did Avid Bioservices' stock split? Avid Bioservices's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are Avid Bioservices' major shareholders? Avid Bioservices' top institutional shareholders include McGuire Investment Group LLC (0.05%), SG Americas Securities LLC (0.04%) and Creative Planning (0.03%). Insiders that own company stock include Nicholas Stewart Green, Joseph Carleone, Daniel R Hart, Richard B Hancock, Mark R Ziebell, Richard A Richieri, Matthew R Kwietniak and Gregory Sargen. View institutional ownership trends. How do I buy shares of Avid Bioservices? Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avid Bioservices investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings9/09/2024Today10/17/2024Next Earnings (Estimated)12/05/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees371Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+33.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-140,750,000.00 Net Margins-101.26% Pretax Margin-15.47% Return on Equity-16.53% Return on Assets-5.60% Debt Debt-to-Equity Ratio2.74 Current Ratio1.46 Quick Ratio1.05 Sales & Book Value Annual Sales$139.91 million Price / Sales4.63 Cash Flow$0.15 per share Price / Cash Flow65.68 Book Value$3.02 per share Price / Book3.36Miscellaneous Outstanding Shares63,790,000Free Float61,849,000Market Cap$647.47 million OptionableOptionable Beta1.38 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CDMO) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avid Bioservices With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.